- Home
- RLGT vs PROK Comparison
RLGT vs PROK Comparison
Compare RLGT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | PROK |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 331.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | PROK |
|---|---|---|
| Price | $7.07 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.00 | $7.40 |
| AVG Volume (30 Days) | 116.4K | ★ 1.1M |
| Earning Date | 02-09-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.35 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $925,786,000.00 | $744,000.00 |
| Revenue This Year | $3.77 | $956.51 |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $23.07 | ★ N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $5.44 | $0.46 |
| 52 Week High | $7.94 | $7.13 |
Technical Indicators
Market Signals| Indicator | RLGT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 44.44 |
| Support Level | $6.96 | $1.71 |
| Resistance Level | $7.26 | $2.18 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 78.41 | 48.92 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.